I

Immatics Biotechnologies

166 employees

Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.

Basic info

Industry

pharmaceuticals

Sectors

Biotechnology
Discovery of HLA-restricted tumor-associated peptides as cancer targets
Immunomonitoring
Adoptive Cell Therapy
TCR-based Immunotherapies
Immunology
TCR Bispecifics
Peptidomics & mass spectrometry
Therapeutics
TCR Discovery
Biomarkers
Medical
Standardized PBMC collection
Bispecific Development
Bioinformatics
Cancer

Date founded

2000

Funding rounds raised

Total raised

$110M

from 30 investors over 30 rounds

I

Immatics Biotechnologies raised undisclosed on September 11, 2023

Investors: Moderna

I

Immatics Biotechnologies raised $35M on July 24, 2023

Investors: Bristol-Myers Squibb, UK

I

Immatics Biotechnologies raised $110M on October 10, 2022

Investors: Dellora Investments, Wellington Management, RTW Investments, LP, Sofinnova Ventures, Russia technology fund, Perceptive Advisors and Samsara BioCapital

I

Immatics Biotechnologies raised $104M on March 17, 2020

Investors: Wellington Partners, Perceptive Advisors, Sphera Fund, RTW Investments, LP and Redmile Group

I

Immatics Biotechnologies raised $75M on September 5, 2019

Investors: Celgene

I

Immatics Biotechnologies raised $58M on October 4, 2017

Investors: Wellington Partners

I

Immatics Biotechnologies raised $30M on January 9, 2017

Investors: Grazia Equity

I

Immatics Biotechnologies raised $16M on October 15, 2013

Investors: Wellington Partners

I

Immatics Biotechnologies raised $71M on September 21, 2010

Investors: MIG Capital and Wellington Partners

I

Immatics Biotechnologies raised $52M on February 8, 2007

Investors: Wellington Partners, -, Swisscom Ventures, 3i Group plc and KfW

FAQ